LETTER TO THE EDITOR
|Year : 2020 | Volume
| Issue : 7 | Page : 43-44
COVID-19 and underlying cerebrovascular disease: Analysis on association
Pathum Sookaromdee1, Viroj Wiwanitkit2
1 TWS Medical Center, Bangkok, Thailand
2 Honorary Professor, Dr DY Patil University, Pune, India; Visiting Professor, Hainan Medical University, Haikou, China
|Date of Submission||09-Apr-2020|
|Date of Decision||09-Apr-2020|
|Date of Acceptance||06-Apr-2020|
|Date of Web Publication||17-Apr-2020|
TWS Medical Center, Bangkok
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Sookaromdee P, Wiwanitkit V. COVID-19 and underlying cerebrovascular disease: Analysis on association. Ann Indian Acad Neurol 2020;23, Suppl S1:43-4
|How to cite this URL:|
Sookaromdee P, Wiwanitkit V. COVID-19 and underlying cerebrovascular disease: Analysis on association. Ann Indian Acad Neurol [serial online] 2020 [cited 2020 May 31];23, Suppl S1:43-4. Available from: http://www.annalsofian.org/text.asp?2020/23/7/43/282797
COVID-19 is a new emerging viral disease that can cause severe respiratory distress. The first patient was reported in Wuhan within the Republic of China, before the disease widespread around the world. The underlying illness is reported for association with severity of COVID-19. Regarding cerebrovascular disease, a Chinese report showed that it is a risk factor for severe COVID-19 infection.
Here, the author would like to present additional data from the second country that the new disease had occurred since early January 2020, Thailand. At present (8th April 2020), the total number of COVID-19 patients with 30 deaths in Thailand is 2,369. Two (0.08%) from all COVID-19 patients have underlying cerebrovascular diseases. Focusing on association between underlying cerebrovascular disease and mortality [Table 1]. The preliminary observation from our setting did not support the association between having underlying cerebrovascular disease and poor outcome of COVID-19. Further analysis based on more data from international settings is recommended to clarify the exact clinical relationship between COVID-19 and cerebrovascular disease.
|Table 1: Association between underlying cerebrovascular disease and mortality|
Click here to view
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Hsia W. Emerging new coronavirus infection in Wuhan, China: Situation in early 2020. Case Study Case Rep 2020;10:8-9.
Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: Evidence from meta-analysis. Aging (Albany NY). 2020 Apr 8;12. doi: 10.18632/aging. 103000. [Epub ahead of print].
Yasri S, Wiwanitkit V. Editorial: Wuhan coronavirus outbreak and imported case. Adv Trop Med Pub Health Int 2019;9:1-2.